Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman Page 1

Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board of Directors

Telomir also announces outgoing and new members of the Board of Directors

TAMPA, Florida, August 12, 2024 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a preclinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related diseases, today announced the passing of its Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., MD. Out of respect and privacy for Dr. Chapman’s family, details of his passing are not being disclosed.